Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis

Journal of Cutaneous Medicine and Surgery

Volumn 9, Issue SUPPL. 1, 2005, Pages 26-32

  Papp, Kim A ^a   Ho, Vincent ^b   Langley, Richard ^c   Lynde, Charles ^d   Poulin, Yves ^e   Shear, Neil ^e   Toole, John ^f   Zip, Catherine ^g  

^a Probity Medical   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY OF MANITOBA   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; IMMUNOGLOBULIN G1; METHOTREXATE; MONOCLONAL ANTIBODY;

BLOOD CLOTTING DISORDER; CANCER; CHILL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; INFECTION; INFLAMMATION; MYALGIA; NAUSEA; PAPULAR RASH; PATIENT EDUCATION; PATIENT MONITORING; PRIORITY JOURNAL; PSORIASIS VULGARIS; REVIEW; T LYMPHOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33747368253     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-006-0104-0     Document Type: Review

References (28)

1. Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. J Clin Pharm Ther 2000; 25:1-10.
2. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137:280-284.
3. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 2002; 138:657-663.
4. Werther WA, Gonzalez TN, OConnor SJ, et al. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996; 157:4986-4995.
5. Shear NH, Langley RG, Ho V. Efalizumab, a reversible T-cell modulator for psoriasis. J Cutan Med Surg 2005; This supplement.
6. Gordon K, Siegfried E, Carey W, et al. Impact of 24 weeks of continuous efalizumab therapy on patient-reported outcomes in patients with moderate to severe plaque psoriasis. Presented at the American Academy of Dermatology Summer Meeting. July 25-29, 2003; Chicago, Illinois. Poster #42.
7. Lebwohl M. Psoriasis. Lancet 2003; 361:1197-1204.
8. Menter A, Craig LL, Sterry W, et al. Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol. In press.
9. Leonardi C, Menter A, Sterry W, et al. Guidelines for the long-term management of plaque psoriasis with continuous efalizumab therapy. Presented at the 3rd European Academy of Dermatology and Venereology Spring Symposium. May 19-22, 2005; Sofia, Bulgaria. Poster #32.
10. Guenther L, Langley RG, Shear NH, et al. Integrating biologic agents into management of moderate-to-severe psoriasis: A Consensus of the Canadian Psoriasis Expert Panel. J Cutan Med Surg. 2004; 85:321-337.
11. Langley RG, Ho V, Lynde C, et al. Recommendations for incorporating biologicals into management of moderate-to-severe plaque psoriasis: individualized patient approaches. J Cutan Med Surg 2005; This supplement.
12. Gottlieb AB, Gordon KB, Hamilton TK, et al. Maintenance of efficacy and safety with continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: final phase IIIb study results. Presented at the 63rd Annual Meeting of the American Academy of Dermatology. February 18-22, 2005; New Orleans, LA. Poster #4.
13. Poulin Y, Papp KA, Carey W, Gulliver W. Efalizumab for long-term control of moderate-to-severe psoriasis. J Cutan Med Surg 2005; This supplement.
14. Raptiva® (efalizumab) US Prescribing Information. Genentech, Inc. 2004.
15. Papp KA and Toth DP. Safety and efficacy of efalizumab retreatment: Final results from an open-label study in psoriasis. Presented at the13th Congress of the European Academy of Dermatology and Venereology. November 17-21, 2004; Florence, Italy. Poster #74.
16. Gordon K, Koo J, Feldman SR, et al. Definitions of measures of effect duration for psoriasis treatments. Psoriasis Forum 2002; 8:1-5.
17. Papp K, Sobell J, Toth D, et al. Safety of subcutaneous efalizumab therapy in patients with moderate to severe plaque psoriasis. Presented at the American Academy of Dermatology Summer Meeting. July 25-29, 2003; Chicago, Ill. Poster #41.
18. Carey W, Glazer S, Gottlieb AB, et al. Relapse, rebound, and psoriasis adverse events: An Advisory Group Report. J Am Acad Dermatol In press 2005.
19. Serono International SA, Data on file, April 2005.
20. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. Invest Dermatol 2003; 120:211-216.
21. McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Safety 2002; 25:913-927.
22. Gordon KB, Feldman SR, Koo JY, et al. Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol. 2005 Jan;141(1):82-4.
23. Menter A, Kardatzke D, Rundle AC, et al. Incidence and prevention of rebound upon efalizumab discontinuation. Poster presentation at the 11th International Psoriasis Symposium. June 15-18, 2005; Toronto, Canada.
24. Maryles S, Rozenblit M, Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. J Dermatolog Treat 2003; 14 Suppl 2:7-16.
25. Koo JY. Current consensus and update on psoriasis therapy: a perspective from the US. J Dermatol 1999; 26:723-733.
26. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28:454-459.
27. Carey W, Rundle AC, Kwon P, Leonardi CL. Taper regimens in the management of patients discontinuing efalizumab therapy. Presented at the 10th Annual International Psoriasis Symposium. June 14-19, 2004; Toronto, Canada. Poster #29.
28. Raptiva® (efalizumab) Canadian Product Monograph. Serono Canada, Inc. 2005.